亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國Tethys Bioscience
美國Tethys Bioscience致力于發現，開發和商品化的新型生物標志物 - 生物標志物 - 這提供了一個實用的工具，以解決諸如糖尿病慢性代謝性疾病越來越多的全球性挑戰。

Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers — biomarkers — that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes.

By developing new tests that use protein and other bloodborne biomarkers to identify people at high risk for devastating and preventable diseases, we can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers give a snapshot of an individual's current risk, which may be modifiable. Our goal is to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Our research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk.

We approach the market with a unique combination of strengths:

A research, management and commercialization team with extensive experience in diagnostic innovation
Alliances with world-class researchers and partners
A solid financial foundation

The company has become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: Biomarkers. The company believes there is a large unmet need in both the discovery of potentially important biomarkers and the eventual use of them in routine clinical practice for many significant diseases.

Tethys Bioscience has built expertise, created significant intellectual property, and is executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. Tethys is focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.

Biomarker discovery efforts are focused on applying advanced research tools to identify important biomarkers associated with diseases that affect many people and are very costly to health care systems throughout the world today.
Clinical validation involves a complex process that results in defining a set of new biomarkers and the application of the resulting test to enhance current clinical practice.
Value creation encompasses the use of sophisticated health economic analyses to define appropriate performance criteria for new biomarkers and the execution of market development strategies to drive the adoption of new biomarkers in clinical practice.